Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
Fiorentino
B
B
Cattedra di Oncologia Medica, Chieti, Italy.
Di Stefano
P
P
Giuliani
C
C
Amatetti
C
C
Tinari
N
N
Natoli
C
C
Garufi
C
C
Iacobelli
S
S
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005134:Eye Neoplasms / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007273:Injections, Intramuscular; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000276:immunology; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D011994:Recombinant Proteins
D000276:Adjuvants, Immunologic; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins